Platelet-active drugs: The relationships among dose, effectiveness, and side effects

Chest

Volumn 119, Issue , 2001, Pages 39S-63S

  Patrono, Carlo ^a   Coller, Barry ^a   Dalen, James E ^b   FitzGerald, Garret A ^b   Fuster, Valentin ^b   Gent, Michael ^b   Hirsh, Jack ^b   Roth, Gerald ^b  

^a Robinette Foundation ^*  (United States)

^b Robinette Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FLURBIPROFEN; HEPARIN; INDOBUFEN; LAMIFIBAN; ORBOFIBAN; PROSTAGLANDIN SYNTHASE INHIBITOR; ROXIFIBAN; SIBRAFIBAN; SULFINPYRAZONE; TICLOPIDINE; TIROFIBAN; TRIFLUSAL;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ANTICOAGULANT THERAPY; ATHEROSCLEROSIS; BLEEDING; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; HUMAN; HYPERTENSION; PHASE 3 CLINICAL TRIAL; PLACENTA INSUFFICIENCY; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; STROKE; TRANSIENT ISCHEMIC ATTACK;

ASPIRIN; CYCLOOXYGENASE INHIBITORS; DIPYRIDAMOLE; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRE-ECLAMPSIA; PREGNANCY; THROMBOSIS;

EID: 0035124920     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.119.1_suppl.39S     Document Type: Article

References (240)

1. Platelet-active drugs: The relationships among dose, effectiveness, and side effects
2. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: A randomised controlled trial
3. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial
4. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation
5. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting
6. Clopidogrel versus ticlopidine after intracoronary stent placement
7. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary-artery stents
8. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors
9. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial; EPISTENT Investigators Evaluation of Platelet IIb/IIIa Inhibitors for Stenting
10. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization
11. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial
12. Difficulties with oral platelet glycoprotein IIb/IIIa receptor antagonists
13. Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
14. The mechanism of the effect of aspirin on human platelets: I. Acetylation of a particulate fraction protein
15. Acetylation of prostaglandin synthase by aspirin
16. Inhibition of platelet prostaglandin synthetase by oral aspirin
17. Arachidonate metabolism in vascular disorders
18. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2
19. 2 synthase
20. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina
21. 2 after low-dose aspirin
22. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects
23. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man
24. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients
25. Clinical pharmacology of platelet cyclooxygenase inhibition
26. Aspirin as an antiplatelet drug
27. 2 but not systemic prostacyclin by controlled-release aspirin
28. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
29. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress
30. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor
31. Dose-related kinetics of aspirin: Presystemic acetylation of platelet cyclo-oxygenase
32. Transdermal modification of platelet function: An aspirin patch system results in marked suppression of platelet cyclooxygenase
33. The effects of aspirin on megakaryocyte prostaglandin production
34. Sensitivity of fatty acid cyclo-oxygenase from human aorta to acetylation by aspirin
35. The role of prostaglandins in platelet function
36. Possible significance of small numbers of functional platelets in a population of aspirin-treated platelets in vitro and in vivo
37. Effects of salicylates on human platelets
38. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease
39. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris
40. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischemic events
41. Does low-dose acetylsalicylic acid prevent stroke after carotid surgery?: A double-blind, placebo-controlled randomized trial
42. European Stroke Prevention Study: II. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
43. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemie stroke
44. Prevention of venous thrombo-embolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression
45. High and low-dose aspirin prophylaxis against venous thromboembolic disease in total hip replacement
46. Prophylaxis of deep vein thrombosis after total hip replacement: Dextran and external compression compared with 1.2 or 0.3 gram of aspirin daily
47. The United Kingdom transient isehemic attack (UK-TIA) aspirin trial: Final results
48. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina: Results of a Veterans Administration cooperative study
49. Aspirin, heparin, or both to treat acute unstable angina
50. Aspirin, sulfinpyrazone, or both in unstable angina
51. Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily): Effects on platelet aggregation and thromboxane formation
52. Improvement in early saphenous vein graft patency after coronary artery bypass surgery with antiplatelet therapy: Results of a Veterans Administration cooperative study
53. Improved graft patency in patients treated with platelet-inhibiting therapy after coronary bypass surgery
54. A comparison of aspirin with placebo in patients treated with warfarin after heart valve replacement
55. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves
56. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: Danger of aspirin compared with dipyridamole
57. Prevention of arterial thromboembolism with acetylsalicylic acid: A controlled clinical study in patients with aortic ball valves
58. Prevention of thrombosis in patients on hemodialysis by low-dose aspirin
59. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2
60. AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia
61. A randomized trial of aspirin and sulfinpyrazone in threatened stroke: The Canadian cooperative study group
62. Controlled trial of aspirin in cerebral ischemia
63. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19, 435 patients with acute ischemic stroke
64. CAST: Randomised placebo-controlled trial of early aspirin use in 20, 000 patients with acute ischemic stroke
65. Aspirin, platelets and thrombosis: Theory and practice
66. Effect of platelet-modifying drugs on arterial thromboembolism in baboons: Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition
67. Pharmacology of platelet inhibitors
68. Aspirin inhibits platelet function independent of the acetylation of cyclo-oxygenase
69. Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclo-oxygenase inhibition
70. Thrombosis Prevention Trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk; the Medical Research Council's General Practice Research Framework
71. High-dose aspirin inhibits shear-induced platelet reaction involving thrombin generation
72. Aspirin acetylates fibrinogen and enhances fibrinolysis: Fibrinolytic effect is independent of changes in plasminogen activator levels
73. Increased blood fibrinolytic activity after aspirin ingestion
74. Fibrinolytic activity after administration of diflunisal and aspirin
75. Influence of acetylsalicylic acid and salicylamide on the coagulation of blood
76. Dose-dependent influence of acetyl-salicylic acid on platelet functions and plasmatic coagulation factors
77. Measurement of thrombin generation in whole blood: The effect of heparin and aspirin
78. Antiplatelet drugs and generation of thrombin in clotting blood
79. Isolation and covalent structure of the aspirin-modified, active-site region of prostaglandin synthetase
80. The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1
81. In vitro acetylation of plasma proteins, enzymes and DNA by aspirin
82. Inhibition of thrombin generation by aspirin is blunted in hypercholesterolemia
83. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis
84. Aspirin dose in stroke prevention: Beautiful hypotheses slain by ugly facts
85. Final report on the aspirin component of the ongoing Physicians' Health Study
86. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
87. COX-2 inhibitors
88. Effects of aspirin on platelet-neutrophil interactions: Role of nitric oxide and endothelin-1
89. Prothrombotic effects of erythrocytes on platelet reactivity: Reduction by aspirin
90. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: The effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity
91. Aspirin protects endothelial cells from oxidative stress: Possible synergism with vitamin E
92. Aspirin improves endothelial dysfunction in atherosclerosis
93. Platelet aggregation in patients with atrial fibrillation talcing aspirin or warfarin
94. Aspirin response and failure in cerebral infarction
95. Development of aspirin resistance in persons with previous ischemic stroke
96. Effects of low dose aspirin on platelet function in patients with recent cerebral ischemia
97. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty
98. Individual variation in the effects of ASA on platelet function: Implications for the use of ASA clinically
99. Persistent inhibition of platelet function during long-term treatment with 75 mg acetylsalicylic acid daily in men with unstable coronary artery disease
100. Two-year follow-up of aspirin responder and aspirin non responder: A pilot-study including 180 post-stroke patients
101. Failure of aspirin treatment after stroke
102. Ex vivo response to aspirin differs in stroke patients with single or recurrent events: A pilot study
103. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance
104. COX-2 is not involved in thromboxane biosynthesis by activated human platelets
105. Dissociation of platelet activation and spontaneous myocardial ischemia in unstable angina
106. Eicosanoids and iso-eicosanoids: Constitutive, inducible and transcellular biosynthesis in vascular disease
107. Pharmacology of platelet inhibition in humans: Implications of the salicylate-aspirin interaction
108. Aspirin as a therapeutic agent in cardiovascular disease
109. Evidence for episodic platelet activation in acute ischemic stroke
110. Platelet activation and lipid peroxidation in patients with acute ischemic stroke
111. Increased platelet activation in the chronic phase after cerebral ischemia and intracerebral hemorrhage
112. Prevention of ischemic stroke
113. Aspirin in ischemic cerebrovascular disease: How strong is the case for a different dosing regimen?
114. Randomised trial of prophylactic daily aspirin in British male doctors
115. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
116. An overview of the British and American aspirin studies
117. Special report: Preliminary report of the Stroke Prevention in Atrial Fibrillation Study
118. Final results
119. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation
120. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK Study
121. Secondary prevention in nonrheumatic atrial fibrillation after transient ischemic attack or minor stroke
122. Atrial fibrillation and stroke: Three new studies, three remaining questions
123. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial
124. Atrial fibrillation and stroke: Revisiting the dilemmas
125. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study
126. Collaborative overview of randomized trials of antiplatelet therapy: III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients
127. Prophylactic agents for venous thrombosis in elective hip surgery
128. Prevention of venous thrombo-embolism
129. An evaluation of impedance plethysmography and I-125-fibrinogen leg scanning in patients following hip surgery
130. A randomized trial of less intensive post-operative warfarin and aspirin therapy in the prevention of venous thrombo-embolism after surgery for fractured hip
131. RD Heparin (ardeparin sodium) vs aspirin to prevent deep venous thrombosis after hip or knee replacement surgery
132. The low molecular weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism following surgery for hip fracture
133. Place of aspirin in prophylaxis of venous thromboembolism
134. A meta-analysis of low dose aspirin for the prevention of pregnancy-induced hypertensive disease
135. Prevention of fetal growth retardation with low-dose aspirin: Findings of the EPREDA trial
136. Low-dose aspirin in prevention and treatment of intrauterine growth retardation and pregnancy-induced hypertension
137. Prevention of pre-eclampsia with low-dose aspirin in healthy, nulliparous pregnant women
138. CLASP: A randomized trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9, 364 pregnant women
139. ECPPA: Randomised trial of low dose aspirin for the prevention of maternal and fetal complications in high-risk pregnant women
140. Barbarados Low dose Aspirin Study in Pregnancy (BLASP): A randomised trial for the prevention of pre-eclampsia and its complications
141. A randomised trial of low dose aspirin for primiparae in pregnancy: The Jamaica Low Dose Aspirin Study Group
142. Low-dose aspirin to prevent preeclampsia in women at high risk
143. Aspirin for preventing and treating pre-eclampsia
144. The gastrointestinal toxicity of aspirin: An overview of randomised controlled trials
145. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs
146. Prophylactic aspirin and risk of peptic ulcer bleeding
147. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs
148. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product
149. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs
150. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs: Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group
151. Prospective study of aspirin use and risk of stroke in women
152. The effects of nonsteroidal anti-inflammatory drugs on human hypertensive vascular disease
153. Improvement of renal function with selective thromboxane antagonism in lupus nephritis
154. Antiplatelet agents and survival: A cohort analysis from the studies of left ventricular dysfunction (SOLVD) trial
155. Clinical effects of early ACE inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: Meta-analysis of individual data from nearly 96, 000 randomized patients
156. Antiplatelet drugs
157. Estimated rate of thromboxane secretion into the circulation of normal humans
158. Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs
159. Differential effects of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women
160. Cyclooxygenase inhibition, platelet function and drug metabolite formation during chronic administration of sulfinpyrazone in man
161. 2 production in patients with myocardial infarction
162. Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus
163. Effects of antiplatelet therapy with indobufen or aspirin-dipyridamole on graft patency 1 year after coronary artery bypass grafting
164. Indobufen versus aspirin plus dipyridamole after coronary artery surgery
165. Indobufen in the prevention of thrombo-embolic complications in patients with heart disease
166. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation
167. A randomized trial comparing ticlopidine hydrochloride with indobufen for the prevention of stroke in high-risk patients (TISS Study): Ticlopidine Indobufen Stroke Study
168. Evaluation of flurbiprofen for prevention of reinfarction and reocclusion after successful thrombolysis or angioplasty in acute myocardial infarction: The Flurbiprofen French Trial
169. Pharmacokinetics of triflusal after single and repeated doses in man
170. A double-blind comparison of rofecoxib and naproxen on the incidence of clinically important upper gastrointestinal events: The VIGOR Trial
171. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS Study: A randomized controlled trial
172. Dipyridamole
173. Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo
174. Ticlopidine and clopidogrel
175. Identification and biological activity of the active metabolite of clopidogrel
176. Antiplatelet treatment with ticlopidine in unstable angina: A controlled multicenter clinical trial
177. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke
178. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients
179. Multicenter double blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications
180. Ticlopidine in the treatment of intermittent claudication: A 21-month double blind trial
181. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine: Results from STIMS, the Swedish Ticlopidine Multicentre Study
182. Prevention of aortocoronary bypass graft occlusion: Beneficial effect of ticlopidine on early and late patency rate of venous coronary bypass grafts: A double-blind study
183. Ticlopidine in unstable angina: A more expensive aspirin?
184. Ticlopidine-associated aplastic anemia: A case report and review of literature
185. Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention
186. The antiaggregating and antithrombotic activity of ticlopidine is potentiated by aspirin in the rat
187. Antiplatelet effects of the addition of acetylsalicylic acid 40 mg daily to ticlopidine in human healthy volunteers
188. A clinical trial comparing three antithrombotic-drug regimens after coronary artery stenting
189. Antiplatelet rather than anticoagulant therapy with coronary stenting
190. Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting: EPISTENT Investigators Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
191. Clopidogrel, a novel antiplatelet and antithrombotic agent
192. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE)
193. Clopidogrel loading dose regimens: Kinetic profile of pharmacodynamic response in healthy subjects
194. Thrombotic thrombocytopenic purpura associated with clopidogrel
195. Clopidogrel inhibition of stent, graft and vascular thrombogenesis with antithrombotic enhancement by aspirin in non-human primates
196. Antagonists of the platelet P2T receptor: A novel approach to antithrombotic therapy
197. Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: With a review of platelet-leukocyte interactions
198. Platelet glycoprotein IIb/IIIa receptor inhibitors
199. Platelet GPIIb/IIIa blockers
200. Platelet glycoprotein IIb/IIIa antagonists: What are the relevant issues concerning their pharmacology and clinical use?
201. Platelet glycoprotein IIb/IIIa inhibitors: Basic and clinical aspects
202. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa
203. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
204. Pharmacodynamic profile of a short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade
205. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
206. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at 6 months
207. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
208. Abciximab-associated profound thrombocytopenia: Therapy with immunoglobulin and platelet transfusion
209. Acute profound thrombocytopenia following c7E3 Fab (abciximab) therapy
210. Readministration of abciximab: Interim report of the ReoPro readministration registry
211. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody: Potential implications for effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis
212. Platelet GPIIb/IIIa antagonists: The first anti-integrin receptor therapeutics
213. Non-peptide fibrinogen receptor antagonists: I. Discovery and design of exosite inhibitors
214. Non-peptide fibrinogen receptor antagonists: II. Optimization of a tyrosine template as a mimic for Arg-Gly-Asp
215. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men
216. MK-383 (L-700, 462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man
217. Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high-risk patients undergoing coronary angioplasty
218. Fibrinogen receptor antagonist-induced thrombocytopenia in chimpanzee and rhesus monkey associated with preexisting drug-dependent antibodies to platelet glycoprotein IIb/IIIa
219. Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors
220. Design of potent and specific integrin antagonists: Peptide antagonists with high specificity for glycoprotein IIb-IIIa
221. 2+ on GP IIb-IIIa interactions with integrilin: Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate
222. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention
223. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous intervention
224. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes
225. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention IMPACT-II
226. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
227. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
228. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
229. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
230. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
231. A randomized trial of potent platelet IIb/IIIa antagonism, heparin, or both in patients with unstable angina: The PARAGON study
232. Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial; the TIMI 14 Investigators
233. First chronic platelet glycoprotein IIb/IIIa integrin blockade: A randomized, placebo-controlled study of xemilofiban in unstable angina with percutaneous coronary interventions
234. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial
235. Oral platelet glycoprotein IIb/IIIa receptor antagonists: The present challenge is safety
236. Monitoring platelet GP IIb/IIIa antagonist therapy
237. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (αIIbβ3) inhibitors
238. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: An OPUS-TIMI 16 substudy
239. Flow cytometric measurements of kinetic and equilibrium binding parameters of arginine-glycine-aspartic acid ligands in binding to glycoprotein IIb/IIIa on platelets